hERG1 channels and Glut-1 as independent prognostic indicators of worse outcome in stage I and II colorectal cancer: A pilot study

Translational Oncology

Volumn 5, Issue 2, 2012, Pages 105-112

  Lastraioli, Elena ^a   Bencini, Lapo ^b   Bianchini, Elisa ^b   Romoli, Maria Raffaella ^a   Crociani, Olivia ^a   Giommoni, Elisa ^c   Messerini, Luca ^a   Gasperoni, Silvia ^c   Moretti, Renato ^b   di Costanzo, Francesco ^c   Boni, Luca ^b   Arcangeli, Annarosa ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY HOSPITAL OF TRIESTE   (Italy)

^c CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE TRANSPORTER 1; MUCIN; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL HERG 1; PROTEIN P53; UNCLASSIFIED DRUG; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; COLORECTAL CANCER; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL;

EID: 84859448786     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11250     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J, and Ward E (2010). Cancer statistics, 2010. CA Cancer J Clin 60, 277-300.
2. O'Connell JB, Maggard MA, and Ko CY (2004). Colon cancer survival rates with the new American Joint Committee on Cancer Sixth Edition Staging. J Natl Cancer Inst 96, 1420-1425.
3. Benson AB III, Schrag D, Somerfield MR, Cohen AM, Figueredo AT, Flynn PJ, Krzyzanowska MK, Maroun J, McAllister P, Van Cutsem E, et al. (2004). American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22, 3408-3419.
4. Thibodeau SN, Bren G, and Schaid D (1993). Microsatellite instability in cancer of the proximal colon. Science 260, 816-819.
5. Lengauer C, Kinzler KW, and Vogelstein B (1997). Genetic instability in colorectal cancers. Nature 386, 623-627.
6. Kim GP, Colangelo LH, Wieand HS, Paik S, Kirsch IR, Wolmark N, Allegra CJ, and National Cancer Institute (2007). Prognostic and predictive roles of high degree microsatellite instability in colon cancer: a National Cancer Institute - National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25, 767-772.
7. Samowitz WS, Holden JA, Curtin K, Edwards SL, Walker AR, Lin HA, Robertson MA, Nichols MF, Gruenthal KM, Lynch BJ, et al. (2001). Inverse relationship between microsatellite instability and K-ras and p53 gene alterations in colon cancer. Am J Pathol 158, 1517-1524.
8. Iacopetta B (2003). TP53 mutation in colorectal cancer. Hum Mutat 21, 271-276.
9. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V, et al. (2010). Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28, 3219-3226.
10. Harris A (2002). Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2, 38-47.
11. Hanahan D and Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
12. Semenza GL (2010). Defining the role of hypoxia-inducible-factor 1 in cancer biology and therapeutics. Oncogene 29, 625-634.
13. Liao D and Johnson RS (2007). Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 26, 281-290.
14. Goethals L, Debucquoy A, Perneel C, Geboes K, Ectors N, De Schutter H, Penninckx F, McBride WH, Begg AC, and Haustermans KM (2006). Hypoxia in human colorectal adenocarcinoma: comparison between extrinsic and potential intrinsic hypoxia markers. Int J Radiation Oncology Biol Phys 65, 246-254.
15. Ferrara N (2010). Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 21, 21-26.
16. Kaluz S, Kaluzová M, Liao SY, Lerman M, and Stanbridge EJ (2009). Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: a one transcription factor (HIF-1) show? Biochim Biophys Acta 1795, 162-172.
17. McGuire BB and Fitzpatrick JM (2009). Biomarkers in renal cell carcinoma. Curr Opin Urol 19, 441-446.
18. Steinbach JP, Klumpp A, Wolburg H, and Weller M (2004). Inhibition of epidermal growth factor receptor signaling protects human malignant glioma cells from hypoxia-induced cell death. Cancer Res 64, 1575-1578.
19. Franovic A, Gunaratnam L, Smith K, Robert I, Patten D, and Lee S (2007). Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci USA 104, 13092-13097.
20. Lastraioli E, Guasti L, Crociani O, Polvani S, Hofmann G, Witchel H, Bencini L, Calistri M, Messerini L, Scatizzi M, et al. (2004). herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res 64, 606-611.
21. Ousingsawat J, Spitzner M, Puntheeranurak S, Terracciano L, Tornillo L, Bubendorf L, Kunzelmann K, and Schreiber R (2007). Expression of voltagegated potassium channels in human and mouse colonic carcinoma. Clin Cancer Res 13, 824-831.
22. Dolderer JH, Schuldes CH, Bockhorn A, Altmannsberger M, Lambers C, von Zabern D, Jonas D, Schwegler H, Linke R, and Schröder UH (2010). HERG1 gene expression as a specific tumor marker in colorectal tissues. Eur J Surg Oncol 36, 72-77.
23. Fontana L, D'Amico M, Crociani O, Biagiotti T, Solazzo M, Rosati B, Arcangeli A, Wanke E, and Olivotto M (2001). Long-termmodulation of HERG channel gating in hypoxia. Biochem Biophys Res Commun 286, 857-862.
24. Masi A, Becchetti A, Restano-Cassulini R, Polvani S, Hofmann G, Buccoliero AM, Paglierani M, Pollo B, Taddei GL, Gallina P, et al. (2005). hERG1 channels are overexpressed in glioblastoma multiforme and modulate VEGF secretion in glioblastoma cell lines. Br J Cancer 93, 781-792.
25. Pillozzi S, Brizzi MF, Bernabei PA, Bartolozzi B, Caporale R, Basile V, Boddi V, Pegoraro L, Becchetti A, and Arcangeli A (2007). VEGFR-1 (FLT-1), β1 integrin and hERG K+ channel form a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood 110, 1238-1250.
26. Pastorekova S, Parkkila S, Parkkila AK, Opavský R, Zelník V, Saarnio J, and Pastorek J (1997). Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 112, 398-408.
27. Galizia G, Lieto E, Ferraraccio F, Orditura M, De Vita F, Castellano P, Imperatore V, Romano C, Ciardiello F, Agostini B, et al. (2004). Determination of molecular marker expression can predict clinical outcome in colon carcinomas. Clin Cancer Res 10, 3490-3499.
28. Cooper R, Sarioǧlu S, Sökmen S, Füzün M, Küpelioǧlu A, Valentine H, Görken IB, Airley R, and West C (2003). Glucose transporter-1 (GLUT-1): a potential marker of prognosis in rectal carcinoma? Br J Cancer 89, 870-876.
29. Korkeila E, Talvinen K, Jaakkola PM, Minn H, Syrjänen K, Sundström J, and Pyrhönen S (2009). Expression of carbonic anhydrase IX suggests poor outcome in rectal cancer. Br J Cancer 100, 874-880.
30. Galizia G, Lieto E, Ferraraccio F, De Vita F, Castellano P, Orditura M, Imperatore V, La Mura A, La Manna G, Pinto M, et al. (2006). Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 13, 823-835.
31. Waf1/Cip1 proteins in colorectal cancer. Virchows Arch 437, 241-247.
32. + channels expression and hERG1 current density in tumor cells. Mol Cell Biol 16, 5043-5060.
33. Schemper M and Smith TL (1996). A note on quantifying follow-up in studies of failure time. Control Clin Trials 17, 343-346.
34. Kaplan EL and Meier P (1958). Non parametric estimation from incomplete observations. J Am Stat Assoc 53, 457-481.
35. Ivanov S, Liao S-Y, Ivanova A, Danilkovitch-Miagkova A, Tarasova N, Weirich G, Merrill MJ, Proescholdt MA, Oldfield EH, Lee J, et al. (2001). Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158, 905-919.
36. Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A, Wilson GD, Turley H, Talks KL, Maxwell PH, et al. (2000). Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 60, 7075-7083.
37. Saarnio J, Parkkila S, Parkkila AK, Haukipuro K, Pastoreková S, Pastorek J, Kairaluoma MI, and Karttunen TJ (1998). Immunohistochemical study of colorectal tumors for expression of a novel transmembrane carbonic anhydrase, MN/CA IX, with potential value as a marker of cell proliferation. Am J Pathol 153, 279-285.
38. Airley R, Evans A, Mobasheri A, and Hewitt SM (2010). Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: study using tissue microarrays. Ann Anat 192, 133-138.